Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
about
Quetiapine versus other atypical antipsychotics for schizophreniaOlanzapine versus other atypical antipsychotics for schizophreniaQuetiapine versus other atypical antipsychotics for schizophreniaEvaluation of the clinical efficacy of asenapine in schizophreniaThe switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia.Quetiapine in the treatment of schizophrenia and related disorders.Response to: A Commentary on "Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders"Effectiveness and tolerability of warm-supplementing kidney yang added to risperidone in improving cognitive impairment in patients with schizophrenia: An 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial.Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review).Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials.Prominent clinical dimension, duration of illness and treatment response in schizophrenia: a naturalistic study.Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial.Changes in cognitive function associated with syndrome changes on two five-factor models of the Positive and Negative Syndrome Scale.Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment.Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia.Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms.Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist–physician collaboration in the outpatient department
P2860
Q24202427-FD958044-5518-4BD9-A22C-0295141C88FDQ24236545-DF06C074-FF5D-417D-824E-5B653933089FQ24240989-225FF717-CEB3-400B-863E-1F4A4D2205B5Q24630385-CC458ED4-BB01-4B23-BBCC-6E5201D5EEADQ33605308-C0E42F4E-ADC3-48B5-8B0A-637CEE1C8E85Q34965927-6C27573D-734F-4D9B-A2EB-9BE2B8D6E086Q35941992-A878686F-6822-4FD0-9FEA-C5CCB3233601Q37672827-034583EF-E6CF-49EB-B716-D911C12FE161Q38350551-84387F32-917C-4AF8-9FE5-70664B57C106Q41569283-8D1FA9A9-85C2-45E5-906B-9F9F6A033140Q42236063-82A75B6F-B6DE-424C-8BFD-4CE9EF683427Q42625709-A09C3F0B-6ECA-4881-A905-C054D7F28BACQ43752043-11BEF008-B0FF-4B86-8E04-9B83FE0AF76DQ50439837-27AFEF84-15D1-454E-8892-878953103847Q50667755-7BD019E0-A4CB-4783-B773-52F10EDFE054Q50769946-9CCFCD22-C5FC-43EA-A3D1-F7334413F641Q59126207-87785AFA-4EE5-4E57-9366-674E3D13F764
P2860
Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Effects of risperidone and que ...... edominantly negative symptoms.
@en
Effects of risperidone and que ...... edominantly negative symptoms.
@nl
type
label
Effects of risperidone and que ...... edominantly negative symptoms.
@en
Effects of risperidone and que ...... edominantly negative symptoms.
@nl
prefLabel
Effects of risperidone and que ...... edominantly negative symptoms.
@en
Effects of risperidone and que ...... edominantly negative symptoms.
@nl
P2093
P2860
P50
P1476
Effects of risperidone and que ...... edominantly negative symptoms.
@en
P2093
Anette Douhet
Ilja Spellmann
Markus Opgen-Rhein
Martin Strassnig
Michael Riedel
Norbert Müller
Rosamaria Valdevit
Sandra Dehning
P2860
P2888
P304
P356
10.1007/S00406-007-0739-X
P577
2007-07-14T00:00:00Z